The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Botanix Pharmaceuticals (BOT) submits a new drug application (NDA) to the US FDA for the use of its sofpironium bromide gel for patients with severe primary axillary hyperhidrosis
  • The company says it is targeting FDA approval for the fourth quarter of 2023, provided the application follows a typical 12-month assessment and review period
  • The FDA filing comes after Botanix’s sofpironium bromide product was approved for sale in Japan, with “outstanding” early sales already achieved, according to the company
  • The company says it will now look for other opportunities to bolster its product pipeline with more late-stage or revenue-producing dermatology products
  • Shares in Botanix are up 6.45 per cent to 6.6 cents at 11:01 am AEST

Botanix Pharmaceuticals (BOT) has submitted a new drug application (NDA) to the FDA for the commercial sale of its sofpironium bromide gel.

The gel is designed to treat primary axillary hyperhidrosis, which Botanix said affected over seven million people in the US alone.

The company said it was targeting FDA approval for the product in the fourth quarter of 2023, provided the application followed a typical 12-month assessment and review period.

The submission follows successful results from Botanix’s phase three trials of the product, which demonstrated “highly statistically significant clinical efficacy and excellent safety”.

Moreover, the product has already been approved for sale in Japan, with “outstanding” early sales already achieved.

Botanix President and Executive Chair Vince Ippolito said the FDA submission was a milestone for the company.

“Approximately 7.3 million people in the US suffer from hyperhidrosis and have the potential to benefit from sofpironium bromide,” Mr Ippolito said.

“We look forward to working closely with the FDA on the approval of sofpironium bromide.”

The company said looking ahead, it now planned to pursue other opportunities to bolster its product pipeline with additional late-stage or revenue-producing dermatology products.

Earlier this month, the company raised $7.5 million via a share placement to fund the costs associated with the sofpironium bromide FDA filing.

Shares in Botanix were up 6.45 per cent to 6.6 cents at 11:01 am AEST.

BOT by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Index breaks a record as Energy stocks surge | January 30, 2025

The ASX200 hit an all time intra-day high of 8,515 points in intra day trade, and…
Offshore drilling platform

Karoon up nearly 8% on strong 4th quarter results, record 2024 revenue

Karoon Energy Ltd has seen its shares perform strongly on the back of results from the…
Cats and dogs and hornets and spiders and two nation states I wont mention are all like DeepSeek and GPT

A jump in Tesla hasn’t wiped the impact of DeepSeek on ASX data stocks. And we haven’t seen shorts yet

Some national mastheads servicing the great minds of this sunkissed country have on Thursday reported a…
Market Update Graphic

ASX Market Update: Bourse hits new all time record

The Aussie index extended yesterday’s gains as investor sentiment remains positive in anticipation of an RBA…